Conference Day Two

Thursday, May 15, 2025

8:00 am Light Breakfast & Morning Networking

8:55 am Chair’s Opening Remarks

Targeting Unmet Areas for Transformative Therapies & Reversal of Disease Progression

9:00 am Refining Patient Stratification & Tailoring Pediatric Therapies to Transform IBD Care

  • Eileen Crowley Assistant Professor & Director, Pediatric IBD Centre, Childrens Hospital Western Ontario

Synopsis

  • Exploring age-specific markers for optimized pediatric IBD management
  • Advancing therapeutic approaches to address pediatric-specific challenges in IBD
  • Developing stratification protocols for personalized treatments in pediatric patients

9:30 am Panel Discussion: Enhancing Precision Medicine & Optimizing Stratification to Deliver Effective Fibrosis Therapies

Synopsis

  • Refining stratification approaches to identify high-risk patients for fibrosis
  • Tailoring therapies based on molecular and genetic fibrosis profiles
  • Can biopharma harness stratification tools to improve therapy outcomes and efficiency?

10:00 am Scientific Poster Session & Networking

Synopsis

Join the Precision Medicine and IBD community in this interactive session, showcasing pioneering research and innovative approaches in IBD care. Attendees will have the chance to share their work, engage with their peers, and discuss advancements shaping the future of precision medicine for IBD.

Supercharging IBD Treatment with Novel Therapeutic Pathways to Deliver Superior & Transformative Patient Care

11:00 am Harnessing PD-1 Agonists for Novel Therapeutic Approaches in Autoimmune Diseases

  • Bryan Linggi Senior Director, Translational Research, AnaptysBio

Synopsis

  • Exploring the novel mechanism of PD-1 agonists in T-cell modulation to treat autoimmune diseases
  • Leveraging biomarker data to refine patient selection and optimize therapeutic outcomes
  • Integrating translational research insights into clinical strategy for ulcerative colitis and other inflammatory conditions (RA)

11:30 am Development of a Novel Immune Checkpoint Enhancer as a Potential Therapeutic Medicine for Ulcerative Colitis

  • Judy Chou President and Chief Executive Officer, AltruBio

Synopsis

  • An in-depth exploration for the capacity of emerging approaches regarding non-immune cells to revolutionize our understanding of IBD
  • Exploring the capacity for precision medicine strategies target these unconventional players to open new avenues for IBD treatment innovation

12:00 pm Targeting CCR9: Advancing Precision Therapies for Inflammatory Bowel Disease

  • Sarah Grant Vice President & Head, Early Clinical Development, Respiratory & Immunology, AstraZeneca

Synopsis

  • Leveraging CCR9 inhibition to improve therapeutic targeting and address IBD heterogeneitys
  • Exploring clinical outcomes and patient stratification strategies for CCR9-targeted therapies
  • Innovating treatment pathways to optimize safety and efficacy in precision medicine for IBD

12:30 pm Lunch Break & Networking

Deciphering Novel Targets & Preclinical Models to Accelerate Precision IBD Therapies & Enhance Clinical Success

1:30 pm Deciphering GPR35: A Novel Target for Epithelial-Driven Therapeutics in IBD

Synopsis

  • Unravelling the role of GPR35 in epithelial biology to address inflammatory bowel disease progression
  • Investigating the therapeutic potential of GPR35 antagonists in preclinical models and patient-derived systems
  • Exploring the use of biomarkers to stratify patients for targeted therapeutic interventions and enhanced clinical outcomes

2:00 pm Roundtable Discussion: Advancing Autoimmune Therapeutics: Precision Approaches to Inflammation

  • Paul Kayne Vice President, Biological Sciences  , Palatin Technologies

Synopsis

  • Exploring innovative therapies to address inflammation in autoimmune diseases
  • Leveraging melanocortin receptor agonists to combat inflammation in ulcerative colitis, bypassing the risks of broad immunosuppressants
  • Advancing precision medicine to improve outcomes for patients with chronic inflammatory conditions

3:00 pm Deciphering the Optimal Preclinical Models for Streamlined Stratification for More Efficacious Clinical Trials

  • Katia Karalis Executive Director, RGC, Regeneron Pharmaceuticals

Synopsis

  • How to identify preclinical models that accurately mimic patient heterogeneity and disease complexity
  • Evaluating the predictive power of preclinical models for improving molecular diagnostic evaluation of patients
  • How can one refine models to reduce clinical trial failure rates and improve translational outcomes

3:30 pm Chair’s Closing Remarks

3:40 pm End of 3rd Precision Medicine in Inflammatory Bowel Disease Summit